Adalimumab Biosimilar Litigation: Sandoz’s settlement with AbbVie
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with... Read More
Case Study – Quick Look up at DCGI approval of Lundbeck’s Brintellix
Posted on15 Oct 2018
TagsBrintellix, CDSCO, codevelopment deal in pharma, comarketing deal in pharma, copromotion deal in pharma, DCGI, Lundbeck, vortioxetine
Comments0
Lundbeck India Private Limited (LIPL) announces the launch of Brintellix (vortioxetine) in India for the treatment of patients suffering from major depressive... Read More
Dr. Reddy’s sells Cloderm cream to EPI Health
Posted on03 Oct 2018
Comments0
Dr. Reddy’s Laboratories’ wholly owned U.S. subsidiary Promius Pharma has sold rights of Cloderm (clocortolone pivalate) cream and its authorised generic to... Read More
DRL to disinvest antibiotics plant to Abu Dhabi-based Neopharma
Dr Reddy’s Laboratories on Monday announced the closure of the sale of its antibiotic manufacturing facility and related assets in Bristol, Tennessee... Read More
Tildrakizumab (Ilumetri): Discovery, Development to Commercialization Case Study
Brand Name: Ilumetri Biomolecule: Tildrakizumab Tildrakizumab was designed to block interleukin-23, a cytokine that plays an important role in managing the immune... Read More
Consequences and progress of Takeda-Shire Buyout
Takeda announced in April it would buy Shire in the largest-ever overseas acquisition by a Japanese company. Although Shire is based in... Read More
Pharma aaquisition: Aurobindo to acquire dermatology and oral solids businesses from Sandoz Inc. for $900 million
Aurobindo Pharma’s US based subsidiary Aurobindo Pharma USA Inc has entered into a definitive agreement with Sandoz Inc., USA, a Novartis division,... Read More
Market Launch and brand positioning of Volini Maxx
Posted on30 Aug 2018
Comments0
Sun Pharma Consumer Healthcare, a division of Sun Pharmaceutical Industries Ltd, has launched Volini Maxx, a strongest pain relief spray. The company... Read More
Insight on Novo Nordisk’s acquisition of Bristol, UK-based Ziylo for $800 million
Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator... Read More
PDL – Depomed’s deal for type 2 diabetes products
PDL BioPharma, Inc. (PDL) announces an amendment to the Royalty Purchase and Sale Agreement (the “Royalty Agreement”) with Depomed, Inc. (Depome”) under... Read More